Genmab — December 2020
-
Det kan så være en af forklaringerne, på at der har været lidt småpres på kursen hen over efteråret.
-
Ja 2021 guiding bliver spændende og specielt hvordan markedet reagere mod det ekstra udgifter der vil komme de kommende år. Cask burn vil stige kraftigt og hvis der kommer et gra grimme nyhedder kan det blive grimt indlig de gode nyheder kommer. Tørken fra sommeren 17 til sommeren 19 var ikke sjov.
-
Det lader til at ALXN/Astrazeneca handlen er lidt mere en fusion end et opkøb - ALXN aktionærerne får usd 60 og 2,12 AStrazeneca ADS’er for hver aktie. ALXN aktionærerne kommer til at sidde på 15% af Astrazeneca efterfølgende
-
Der er flere problematiske ting i sådan en konstruktion - men nok meget forventeligt efter ALXNs vandrette udvikling de sidste 4-5 år
-
Mandagens danske avisuddrag med EU, Mærsk og Ørsted: https://www.proinvestor.com/investornyt/670339/mandagens-danske-avisuddrag-med-eu-maersk-og-orsted
-
Private equity firm EQT makes public offer for Swedish pharma maker Recipharm
-
Det er ikke småpenge, der bliver smidt på de selskaber - mon vi kan tale om et åbent m&a vindue lige nu?
-
Lillebror holder R&D dag på onsdag. https://ir.ymabs.com/news-releases/news-release-details/y-mabs-host-virtual-research-development-day-wednesday-december Nogen der følger den?
-
Novo Holdings Creates New Rare Bleeding Disorder Company, Hemab https://www.prnewswire.co.uk/news-releases/novo-holdings-creates-new-rare-bleeding-disorder-company-hemab-854828075.html
-
-
Funded through Novo Seeds' company creation and building efforts
-
Focus on rare underserved bleeding disorders with large unmet need
-
Brings together a strong industrial R&D team with deep expertise in hemophilia and clinically validated technologies from Novo Nordisk and Genmab A/S
-
-
Der sker det som plejer...business as usual..rollercoaster;.)
-
-
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab https://clinicaltrials.gov/ct2/show/NCT04667117?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Teprotumumab+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+duobody+OR+hexabody+OR+Teclistamab+OR+Amivantamab+OR+Talquetamab+OR+Epcoritamab+OR+DuoHexabody&lupd_s=12%2F12%2F2020&draw=2&rank=1
-
Not long ago it was published in some MS-news that Ocrevus might have this issue with loss of vaccinal immunity. I assume that's why Novartis wants to find out whether that goes for ofa as well. Would not be good. Especially if it is also an issue with the corona vaccines.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind